Tag: plasma protein therapeutics market forecast

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Does The Market Size Of The Plasma Protein Therapeutics Industry Compare Between 2025 And 2029?

The plasma protein therapeutics market has experienced significant growth in recent years. It is anticipated to expand from $32.22 billion in 2024 to $34.68 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 7.6%. Historically, this expansion has been influenced by factors such as the increasing occurrence of rare diseases, a growing elderly demographic, the global availability of blood plasma, an uptick in hemophilia instances, advancements in diagnostic methods, and a favorable regulatory environment.

The plasma protein therapeutics market is projected to experience substantial growth in the coming years, with its size anticipated to reach $45.58 billion by 2029, growing at a compound annual growth rate (CAGR) of 7.1%. This expansion is attributed to factors such as gene therapy advancements, increasing healthcare expenditure, expanded indications, precision medicine approaches, and patient access programs. Significant trends expected during this period include technological innovations, telemedicine adoption, advancements in plasma fractionation technology, the development of next-generation therapies, the adoption of recombinant therapies, and personalized medicine approaches.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9213&type=smp

Which Drivers Are Supporting Growth Of The Plasma Protein Therapeutics Market?

The rising incidence of autoimmune conditions is anticipated to fuel the expansion of the plasma protein therapeutics market in the future. Such a disorder arises when the immune system of the body mistakenly targets and damages its own healthy cells. Therapeutic plasma exchange offers a treatment for these diseases, which manifest when the body incorrectly identifies a component of itself as alien, subsequently generating proteins (termed autoantibodies) that attack this misidentified bodily part. For example, in May 2023, research carried out by the University of Glasgow, a public university located in the UK, surveyed 22 million individuals and revealed that autoimmune disorders impact approximately 10% of the UK’s population, surpassing prior projections. Consequently, the growing prevalence of autoimmune disorders is a key factor propelling the development of the plasma protein therapeutics market moving ahead.

What Are The Major Segment Types Covered In The Plasma Protein Therapeutics Market?

The plasma protein therapeutics market covered in this report is segmented –

1) By Product: Immunoglobulin, Albumin, Coagulation Factor, C1-esterase Inhibitors, Other Products

2) By Route Of Administration: Intravenous, Subcutaneous

3) By Applications: Primary Immunodeficiency Disorder (PID), Idiopathic Thrombocytopenic Purpura, Secondary Immunodeficiency, Hereditary Angioedema, Other Applications

Subsegments:

1) By Immunoglobulin: Intravenous Immunoglobulin (IVIG), Subcutaneous Immunoglobulin (SCIG)

2) By Albumin: Human Serum Albumin, Recombinant Albumin

3) By Coagulation Factor: Factor VIII, Factor IX, Prothrombin Complex Concentrates

4) By C1-Esterase Inhibitors: Human C1-Esterase Inhibitors, Recombinant C1-Esterase Inhibitors

5) By Other Products: Fibrinogen, Alpha-1 Antitrypsin, Clotting Factor Concentrates

Which Market Trends Are Creating New Opportunities In The Plasma Protein Therapeutics Industry?

Product innovations represent a significant trend gaining traction within the plasma protein therapeutic gaining market. Major companies operating in the plasma protein therapeutic sector are concentrating on developing inventive products to achieve a competitive edge. For illustration, in October 2023, Octapharma AG, a company based in Switzerland, secured approval from European medical authorities for the lyophilized variant of its widely recognized product, octaplasLG. This advanced formulation is specifically engineered for pre-hospital transfusion, thereby furnishing healthcare professionals with a practical and efficacious alternative for managing patients in critical scenarios. The approval emphasizes Octapharma’s unwavering dedication to elevating patient care through ground-breaking solutions in the domain of blood products.

Which Key Players Are Driving Competition In The Plasma Protein Therapeutics Market?

Major companies operating in the plasma protein therapeutics market include CSL Behring LLC, Grifols SA, China Biologic Products Holdings Inc., Takeda Pharmaceutical Company Limited, Baxter International Inc., Kedrion SpA, LFB SA, Emergent BioSolutions Inc., Reliance Life Sciences Private Limited, ADMA Biologics Inc., Prothya Biosolutions BV, Bio Products Laboratory Ltd., Biotest AG, Taibang Biological Group Co Ltd, Octapharma Plasma Inc., New York Blood Center, Green Cross Corporation, China National Biotec Group Company Limited, Kamada Ltd., Australian Red Cross Lifeblood

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/plasma-protein-therapeutics-global-market-report

How Is Plasma Protein Therapeutics Market Demand Varying Across Different Regions?

North America was the largest region in the plasma protein therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the plasma protein therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The Plasma Protein Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/customise?id=9213&type=smp

Browse Through More Reports Similar to the Global Plasma Protein Therapeutics Market 2025, By The Business Research Company

Blood Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report

Cancer Biologics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report

Rituximab Biosimilar Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/rituximab-biosimilar-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Latest Market Insights for the Plasma Protein Therapeutics Industry?

In recent years, the market size of plasma protein therapeutics has seen robust growth. Its growth will rise from $32.22 billion in 2024 to $34.68 billion in 2025, marking a compound annual growth rate (CAGR) of 7.6%. The historical growth of this market is linked to factors such as a rise in rare diseases, an increasing elderly population, the worldwide supply of blood plasma, an increase in hemophilia cases, enhancements in diagnostic procedures, and a conducive regulatory environment.

It is anticipated that the plasma protein therapeutics market’s size will robustly grow in the coming years. The market is projected to reach “$45.58 billion in 2029 at a compound annual growth rate (CAGR) of 7.1%. The surge in size during the forecast period can be associated with developments in gene therapy, increased spending in healthcare, broader application areas, precision medicine techniques, and patient accessibility programs. Noteworthy tendencies in the forecast era involve technological revolutions, adoption of telemedicine, advancements in plasma fractionation technology, the creation of next-generation therapies, acceptance of recombinant therapies, and personalized medicine strategies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9213&type=smp

What Forces Are Driving The Growth Of The Plasma Protein Therapeutics Industry?

The rise in autoimmune disorders is anticipated to fuel the expansion of the plasma protein therapeutics market. Autoimmune disorders occur when the body’s immune system mistakenly attacks and destroys healthy cells. Autoimmune diseases, which develop when the body erroneously identifies a part of itself as alien and creates proteins (autoantibodies) that assault the misinterpreted part of the body, are treated with therapeutic plasma exchange. For example, research involving 22 million people undertaken by the University of Glasgow, a public university in the UK, discovered in May 2023 that approximately 10% of the UK’s population suffers from autoimmune disorders, surpassing previous predictions. As a result, the growing incidence of autoimmune disorders is propelling the advancement of the plasma protein therapeutics market.

What Is The Overview Of Market Segmentation In The Plasma Protein Therapeutics Industry?

The plasma protein therapeutics market covered in this report is segmented –

1) By Product: Immunoglobulin, Albumin, Coagulation Factor, C1-esterase Inhibitors, Other Products

2) By Route Of Administration: Intravenous, Subcutaneous

3) By Applications: Primary Immunodeficiency Disorder (PID), Idiopathic Thrombocytopenic Purpura, Secondary Immunodeficiency, Hereditary Angioedema, Other Applications

Subsegments:

1) By Immunoglobulin: Intravenous Immunoglobulin (IVIG), Subcutaneous Immunoglobulin (SCIG)

2) By Albumin: Human Serum Albumin, Recombinant Albumin

3) By Coagulation Factor: Factor VIII, Factor IX, Prothrombin Complex Concentrates

4) By C1-Esterase Inhibitors: Human C1-Esterase Inhibitors, Recombinant C1-Esterase Inhibitors

5) By Other Products: Fibrinogen, Alpha-1 Antitrypsin, Clotting Factor Concentrates

Which Trends Are Redefining The Future Landscape Of The Plasma Protein Therapeutics Industry?

Innovations in product development are becoming increasingly prevalent in the plasma protein therapeutics market, constituting a key trend. Many prominent companies in this sector are leveraging novel products to maintain a competitive edge in the market. One such example can be found in Octapharma AG, a Swiss enterprise that in October 2023, had received the green light from European medical bodies for its lyophilized version of their renowned product, octaplasLG. Constructed for pre-hospital transfusions, this advanced product offers healthcare providers an efficient and pragmatic solution for handling patients during emergencies. This approval emphasizes Octapharma’s dedication to augmenting patient care by pioneering innovative blood product solutions.

Who Are The Primary Players Operating Across The Global Plasma Protein Therapeutics Market?

Major companies operating in the plasma protein therapeutics market include CSL Behring LLC, Grifols SA, China Biologic Products Holdings Inc., Takeda Pharmaceutical Company Limited, Baxter International Inc., Kedrion SpA, LFB SA, Emergent BioSolutions Inc., Reliance Life Sciences Private Limited, ADMA Biologics Inc., Prothya Biosolutions BV, Bio Products Laboratory Ltd., Biotest AG, Taibang Biological Group Co Ltd, Octapharma Plasma Inc., New York Blood Center, Green Cross Corporation, China National Biotec Group Company Limited, Kamada Ltd., Australian Red Cross Lifeblood

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/plasma-protein-therapeutics-global-market-report

Which Region Offers The Most Growth Potential For The Plasma Protein Therapeutics Market Through 2029?

North America was the largest region in the plasma protein therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the plasma protein therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=9213&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the plasma protein therapeutics industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

#What Are the Key Projections for the CAGR of the Plasma Protein Therapeutics Market Size From 2025 to 2034?_x000D_

In recent times, there has been a significant growth in the market size of plasma protein therapeutics. The market, which was valued at $31.86 billion in 2024, is projected to reach $34.55 billion in 2025, registering a compound annual growth rate (CAGR) of 8.5%. This growth trend during the historical period is due to factors such as the increasing prevalence of rare diseases, an increase in the aging population, the growing supply of global blood plasma, a rise in hemophilia cases, advancements in diagnostic techniques, and a supportive regulatory environment._x000D_

_x000D_

The market for plasma protein therapeutics is predicted to witness robust expansion in the coming years. Projected to reach $46.35 billion by 2029, it aims to grow at a compound annual growth rate (CAGR) of 7.6%. The anticipated growth in this timeframe is due to advancements in gene therapy, rising healthcare costs, broadened applications, precision medical strategies, and patient access initiatives. Key trends expected in this period encompass technological breakthroughs, the implementation of telemedicine, advancements in plasma fractionation technology, the emergence of next-generation therapies, the adoption of recombinant therapies, and the application of personalized medicine._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=9213&type=smp_x000D_

_x000D_

#What Are the Major Market Drivers Behind the Rising Adoption of Plasma Protein Therapeutics Market?#_x000D_

The anticipated increase in autoimmune diseases is projected to boost the expansion of the plasma protein therapeutics market. Autoimmune disorders occur when the body’s immune system mistakenly assaults and destroys healthy cells. To treat these disorders, therapeutic plasma exchange is utilized, as these diseases arise when the body mistakenly perceives a part of itself as alien and develops proteins (referred to as autoantibodies) that assail the erroneously identified part of the body. For example, research carried out by the University of Glasgow in May 2023, involving 22 million individuals, revealed that autoimmune disorders impact around 10% of the UK’s populace, surpassing past predictions. Consequently, the rising frequency of autoimmune disorders is pushing the growth of the plasma protein therapeutics market._x000D_

_x000D_

#Which Key Market Segments Comprise the Plasma Protein Therapeutics Market and Drive Its Revenue Growth?#_x000D_

The plasma protein therapeutics market covered in this report is segmented –_x000D_

_x000D_

1) By Product: Immunoglobulin, Albumin, Coagulation Factor, C1-esterase Inhibitors, Other Products_x000D_

2) By Route Of Administration: Intravenous, Subcutaneous_x000D_

3) By Applications: Primary Immunodeficiency Disorder (PID), Idiopathic Thrombocytopenic Purpura, Secondary Immunodeficiency, Hereditary Angioedema, Other Applications_x000D_

_x000D_

Subsegments:_x000D_

1) By Immunoglobulin: Intravenous Immunoglobulin (IVIG), Subcutaneous Immunoglobulin (SCIG)_x000D_

2) By Albumin: Human Serum Albumin, Recombinant Albumin_x000D_

3) By Coagulation Factor: Factor VIII, Factor IX, Prothrombin Complex Concentrates_x000D_

4) By C1-Esterase Inhibitors: Human C1-Esterase Inhibitors, Recombinant C1-Esterase Inhibitors_x000D_

5) By Other Products: Fibrinogen, Alpha-1 Antitrypsin, Clotting Factor Concentrates_x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=9213&type=smp_x000D_

_x000D_

#Which Areas Are Leading Regions in the Plasma Protein Therapeutics Market Expansion Across the Globe?#_x000D_

North America was the largest region in the plasma protein therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the plasma protein therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa_x000D_

_x000D_

#What Are the Strategic Trends Steering thePlasma Protein Therapeutics Market Direction?#_x000D_

Product developmental innovations are steadily emerging as a main trend in the plasma protein therapeutic market. Key companies in this field are concentrating their efforts on creating innovative products in order to stand out from their competitors. As an example, Octapharma AG, a company hailing from Switzerland, received approval for the lyophilized version of their well-known product, octaplasLG, in October 2023. This new version is intended for use in pre-hospital transfusions, giving healthcare professionals a reliable and effective solution to handle patients in crucial circumstances. This approval highlights Octapharma’s dedication to improving patient care via ground-breaking solutions in the area of blood products._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/plasma-protein-therapeutics-global-market-report_x000D_

_x000D_

#How Is the Plasma Protein Therapeutics Market Conceptually Defined?#_x000D_

Plasma protein therapeutics refers to therapies derived from plasma and their recombinant analogs. It is used for the treatment of specific medical conditions by replacing missing or deficient proteins found in plasma, allowing recipients to live healthier and more productive lives._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9213_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 3156230293_x000D_

Asia +44 2071930708_x000D_

Europe +44 2071930708_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

Which Primary Drivers Are Supporting the Continued Market Growth of thePlasma Protein Therapeutics Market?

The escalation in the frequency of autoimmune diseases is anticipated to stimulate the expansion of the plasma protein therapeutics market in the future. Autoimmune disorders occur when the body’s defense mechanism mistakenly assaults and obliterate its healthy cells. To address such diseases, therapeutic plasma exchanges are often executed. These illnesses result when the body incorrectly perceives a segment of itself as alien and generates proteins, also known as autoantibodies, that assault the part of the body which has been wrongly recognized. For example, in May 2023, a study by the University of Glasgow, a public university in the UK, which encompassed 22 million people, discovered that about 10% of the UK’s population is struck by autoimmune disorders, a figure that surpasses previous approximations. As such, the surge in the incidence of autoimmune disorders is contributing to the growth of the plasma protein therapeutics market in the future.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9213&type=smp

#How Will the CAGR of the Plasma Protein Therapeutics Market Influence Its Overall Growth by 2034?

In recent years, the plasma protein therapeutics market has experienced substantial growth. The market is projected to escalate from $31.86 billion in 2024 to $34.55 billion in 2025, with an 8.5% compound annual growth rate (CAGR). The surge during the historical period is linked to the increasing incidence of rare diseases, an expanding elderly population, a global increase in blood plasma supply, a rise in hemophilia instances, diagnostic advancements, and a regulatory environment that fosters growth.

The market for plasma protein therapeutics is projected to experience robust expansion in the coming years, escalating to $46.35 billion in 2029 with a compound annual growth rate (CAGR) of 7.6%. The projected growth over the forecast period can be credited to advances in gene therapy, higher healthcare spending, more comprehensive indications, precision medicine tactics, and patient access programs. The forecast period is also set to see major trends like technological innovations, the integration of telemedicine, advancements in plasma fractionation technology, the creation of next-generation therapies, the use of recombinant therapies, and personalized medicine strategies.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9213

How Are Consumer Market Innovations Shaping the Current and Future Landscape of thePlasma Protein Therapeutics Market?

The proliferation of product advancements is a central trend taking hold in the plasma protein therapeutic market. Leading firms in this sector are channeling innovation to gain leverage in the intensely competitive landscape. For example, Octapharma AG, a Swiss conglomerate, secured approval from European medical regulatory bodies for the freeze-dried variant of their flagship product, octaplasLG, in October 2023. This progressive formulary is designed for the convenience of pre-hospital transfusions, giving healthcare practitioners an optimal management strategy for patients in critical conditions. This approval fortifies Octapharma’s dedication to improve patient healthcare by introducing inventive resolutions in the blood products field.

Who Are the Key Market Players Influencing the Growth of the Corn and Plasma Protein Therapeutics Industry?

Major companies operating in the plasma protein therapeutics market include CSL Behring LLC, Grifols SA, China Biologic Products Holdings Inc., Takeda Pharmaceutical Company Limited, Baxter International Inc., Kedrion SpA, LFB SA, Emergent BioSolutions Inc., Reliance Life Sciences Private Limited, ADMA Biologics Inc., Prothya Biosolutions BV, Bio Products Laboratory Ltd., Biotest AG, Taibang Biological Group Co Ltd, Octapharma Plasma Inc., New York Blood Center, Green Cross Corporation, China National Biotec Group Company Limited, Kamada Ltd., Australian Red Cross Lifeblood

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/plasma-protein-therapeutics-global-market-report

Which Key Market Segments Comprise the Plasma Protein Therapeutics Market and Drive Its Revenue Growth?

The plasma protein therapeutics market covered in this report is segmented –

1) By Product: Immunoglobulin, Albumin, Coagulation Factor, C1-esterase Inhibitors, Other Products

2) By Route Of Administration: Intravenous, Subcutaneous

3) By Applications: Primary Immunodeficiency Disorder (PID), Idiopathic Thrombocytopenic Purpura, Secondary Immunodeficiency, Hereditary Angioedema, Other Applications

Subsegments:

1) By Immunoglobulin: Intravenous Immunoglobulin (IVIG), Subcutaneous Immunoglobulin (SCIG)

2) By Albumin: Human Serum Albumin, Recombinant Albumin

3) By Coagulation Factor: Factor VIII, Factor IX, Prothrombin Complex Concentrates

4) By C1-Esterase Inhibitors: Human C1-Esterase Inhibitors, Recombinant C1-Esterase Inhibitors

5) By Other Products: Fibrinogen, Alpha-1 Antitrypsin, Clotting Factor Concentrates

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=9213&type=smp

Which Regions Are Emerging as Leaders in the Plasma Protein Therapeutics Market?

North America was the largest region in the plasma protein therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the plasma protein therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Reports Similar to the Gobal Plasma Protein Therapeutics Maret 2025, By The Business Research Company:

Blood Cancer Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report

Rituximab Biosimilars Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/rituximab-biosimilar-global-market-report

Isothermal Nucleic Acid Amplification Technology (INAAT) Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/isothermal-nucleic-acid-amplification-technology-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What key factors are powering the surge in the plasma protein therapeutics market right now?

There has been a significant expansion in the size of the plasma protein therapeutics market in the recent past. The market, valued at $31.86 billion in 2024, is poised to reach $34.55 billion in 2025, reflecting a compound annual growth rate (CAGR) of 8.5%. Factors contributing to its growth during the previous years include the rising incidence of rare diseases, an increase in the elderly population, an ample supply of blood plasma globally, a surge in hemophilia cases, advancements in diagnostic methods, and supportive regulatory landscape.

How fast Is the plasma protein therapeutics market expected to grow, and what’s its future value?

Projected to experience robust growth in the coming years, the market size for plasma protein therapeutics is expected to reach $46.35 billion in 2029, progressing at a compound annual growth rate (CAGR) of 7.6%. The anticipated growth during the forecast period is primarily driven by advancements in gene therapy, heightened healthcare spending, the expansion of indications, precision medicine techniques, and patient access programs. Key predicted trends for the forecast period encompass technological breakthroughs, the incorporation of telemedicine, progressive advancements in plasma fractionation technology, the generation of next-level therapies, the application of recombinant therapies, and personalized medicine strategies.

Get your plasma protein therapeutics market report here!

https://www.thebusinessresearchcompany.com/report/plasma-protein-therapeutics-global-market-report

What are the leading drivers of growth in the plasma protein therapeutics market?

The plasma protein therapeutics market’s expansion is anticipated to be driven by a growing occurrence of autoimmune diseases. A condition where the body’s immune system targets and eradicates healthy cells is known as an autoimmune disease. Therapeutic plasma exchange, used in treating these diseases, occurs when the body falsely identifies a part of itself as foreign, producing proteins (known as autoantibodies) that attack the wrongly identified body part. In May 2023, a research involving 22 million people by the University of Glasgow, a public university in the UK, revealed that autoimmune diseases affect around 10% of the UK population, surpassing previous estimates. Consequently, the rising occurrence of autoimmune diseases is fuelling the growth of the plasma protein therapeutics market in the future.

What are the key segments defining the plasma protein therapeutics market?

The plasma protein therapeutics market covered in this report is segmented –

1) By Product: Immunoglobulin, Albumin, Coagulation Factor, C1-esterase Inhibitors, Other Products

2) By Route Of Administration: Intravenous, Subcutaneous

3) By Applications: Primary Immunodeficiency Disorder (PID), Idiopathic Thrombocytopenic Purpura, Secondary Immunodeficiency, Hereditary Angioedema, Other Applications

Subsegments:

1) By Immunoglobulin: Intravenous Immunoglobulin (IVIG), Subcutaneous Immunoglobulin (SCIG)

2) By Albumin: Human Serum Albumin, Recombinant Albumin

3) By Coagulation Factor: Factor VIII, Factor IX, Prothrombin Complex Concentrates

4) By C1-Esterase Inhibitors: Human C1-Esterase Inhibitors, Recombinant C1-Esterase Inhibitors

5) By Other Products: Fibrinogen, Alpha-1 Antitrypsin, Clotting Factor Concentrates

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9213&type=smp

Who are the key players steering the development of the plasma protein therapeutics market?

Major companies operating in the plasma protein therapeutics market include CSL Behring LLC, Grifols SA, China Biologic Products Holdings Inc., Takeda Pharmaceutical Company Limited, Baxter International Inc., Kedrion SpA, LFB SA, Emergent BioSolutions Inc., Reliance Life Sciences Private Limited, ADMA Biologics Inc., Prothya Biosolutions BV, Bio Products Laboratory Ltd., Biotest AG, Taibang Biological Group Co Ltd, Octapharma Plasma Inc., New York Blood Center, Green Cross Corporation, China National Biotec Group Company Limited, Kamada Ltd., Australian Red Cross Lifeblood

What emerging trends are influencing the growth of the plasma protein therapeutics market?

One notable trend gaining traction in the plasma protein therapeutic market is product innovation. Many large-scale enterprises in this field are zeroing in on pioneering products as a way to establish their market dominance. An apt illustration of this is Octapharma AG, a company based in Switzerland that in October 2023 received authorization from European health regulators for the freeze-dried variant of its acclaimed product, octaplasLG. Conceived for pre-hospital transfusion, this evolved formulation gives healthcare providers an accessible and potent solution for treating critically ill patients. The granted approval highlights Octapharma’s dedication towards improving patient care by offering innovative blood product solutions.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9213

Which regions are most influential in expanding the plasma protein therapeutics market?

North America was the largest region in the plasma protein therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the plasma protein therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Similar Reports By The Business Research Company:

Blood Cancer Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report

Rituximab Biosimilars Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/rituximab-biosimilar-global-market-report

Isothermal Nucleic Acid Amplification Technology (INAAT) Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/isothermal-nucleic-acid-amplification-technology-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What is the Forecasted Expansion Rate of the Plasma Protein Therapeutics Market Over the 2025–2034 Period?

There has been a significant increase in the size of the plasma protein therapeutics market in the previous years. The market size is predicted to elevate from $31.86 billion in 2024 to about $34.55 billion in 2025, marking a compound annual growth rate (CAGR) of 8.5%. This substantial growth during the past period has been influenced by factors such as growing number of rare diseases, an aging global population, an increase in the supply of blood plasma, a surge in hemophilia cases, advancements in diagnosis techniques, and a favorable regulatory framework.

Expectations are high that the plasma protein therapeutics market will see robust growth in the coming years. The market is predicted to reach $46.35 billion by 2029, with a compound annual growth rate (CAGR) of 7.6%. Factors contributing to this anticipated growth in the forecast period include progress in gene therapy, higher healthcare expenditure, extended indications, precision medicine methodologies, and patient access programs. In addition, major trends for the future include embracing telemedicine, innovative technology, advancements in plasma fractionation technology, pioneering next-generation therapies, and adopting recombinant and personalized medicine therapies.

What External and Internal Drivers Are Contributing to the Growth of the plasma protein therapeutics Market’s Growth?

The plasma protein therapeutics market’s future growth is expected to be driven by the increasing emergence of autoimmune disorders. This occurs when the body’s immune system wrongly attacks healthy cells, considering them foreign. To handle these autoimmune diseases, therapeutic plasma exchange is employed, which comes to light when the body generates proteins, known as autoantibodies, that mistakenly attack the body’s own part. For instance, research carried out by the UK’s University of Glasgow in May 2023, involving a whopping 22 million people, disclosed that approximately 10% of the UK population is affected by autoimmune disorders, which is more than previously assumed. Therefore, the escalating prevalence of autoimmune disorders is putting the plasma protein therapeutics market on an upward trajectory.

Get Your Free Sample of the Global Plasma Protein Therapeutics Market Report Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=9213&type=smp

Who Are the Leading Organizations Fueling the Expansion of the Plasma Protein Therapeutics Market?

Major companies operating in the plasma protein therapeutics market include:

• CSL Behring LLC_x000D_

• Grifols SA_x000D_

• China Biologic Products Holdings Inc._x000D_

• Takeda Pharmaceutical Company Limited_x000D_

• Baxter International Inc._x000D_

Which Cutting-Edge Trends Are Expected to Drive the Plasma Protein Therapeutics Market’s Growth?

One key trend making waves in the plasma protein therapeutic market is the drive for product innovations. Companies at the forefront of this sector are placing a significant emphasis on the development of innovative offerings in order to carve out a competitive edge in the market. An illustrative example of this trend was seen in October 2023, when Octapharma AG, a company based in Switzerland, attained approval from European medical authorities for their lyophilized form of the well-known product, octaplasLG. This enhanced version is tailored for pre-hospital transfusions, offering healthcare specialists a practical and efficient solution for the management of patients in dire situations. This development not only stresses Octapharma’s commitment to upgrade patient care, but also reinforces their dedication to fostering innovation in the sphere of blood products.

Get Instant Access to the Global Plasma Protein Therapeutics Market Report with Swift Delivery!

https://www.thebusinessresearchcompany.com/report/plasma-protein-therapeutics-global-market-report

What Are the Core Categories and Segments in the Plasma Protein Therapeutics Market Driving Demand and Growth?

The plasma protein therapeutics market covered in this report is segmented –

1) By Product: Immunoglobulin, Albumin, Coagulation Factor, C1-esterase Inhibitors, Other Products

2) By Route Of Administration: Intravenous, Subcutaneous

3) By Applications: Primary Immunodeficiency Disorder (PID), Idiopathic Thrombocytopenic Purpura, Secondary Immunodeficiency, Hereditary Angioedema, Other Applications

Subsegments:

1) By Immunoglobulin: Intravenous Immunoglobulin (IVIG), Subcutaneous Immunoglobulin (SCIG)

2) By Albumin: Human Serum Albumin, Recombinant Albumin

3) By Coagulation Factor: Factor VIII, Factor IX, Prothrombin Complex Concentrates

4) By C1-Esterase Inhibitors: Human C1-Esterase Inhibitors, Recombinant C1-Esterase Inhibitors

5) By Other Products: Fibrinogen, Alpha-1 Antitrypsin, Clotting Factor Concentrates

Which Regions Are Most Influential in Expanding the Plasma Protein Therapeutics Market?

North America was the largest region in the plasma protein therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the plasma protein therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Key Parameters Define the Plasma Protein Therapeutics Market’s Scope?

Plasma protein therapeutics refers to therapies derived from plasma and their recombinant analogs. It is used for the treatment of specific medical conditions by replacing missing or deficient proteins found in plasma, allowing recipients to live healthier and more productive lives.

Browse Through More Similar Reports By The Business Research Company:

Blood Cancer Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report

Rituximab Biosimilars Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/rituximab-biosimilar-global-market-report

Isothermal Nucleic Acid Amplification Technology (INAAT) Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/isothermal-nucleic-acid-amplification-technology-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: